AI assistant
ACUSENSUS LIMITED. — Director's Dealing 2025
Nov 20, 2025
64287_rns_2025-11-20_777f9e6f-fd38-4f33-b62c-97fafa74878b.pdf
Director's Dealing
Open in viewerOpens in your device viewer
==> picture [180 x 35] intentionally omitted <==
Appendix 3Y Change of Director’s Interest Notice
1Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Acusensus Limited ABN 17 625 231 941
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Alexander Jannink |
|---|---|
| Date of last notice | 4 September 2025 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Indirect |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
Alexander Jannink is a director, shareholder and beneficiary of Jannink & Associates Pty Ltd ACN 622 744 870 as trustee for Jannink FamilyTrust |
| Date of change | 20 November 2025 |
| No. of securities held prior to change | 1. 15,331,066 fully paid ordinary shares. 2. 510,660 unquoted options: a. 210,000 unquoted options exercisable at A$0.552 and expire on 20 April 2027; b. 220,500 unquoted options exercisable at A$0.552 and expire on 30 June 2027; and c. 80,160 unquoted options exercisable at A$0.552 and expire on 26 September 2031. 3. 307,745 unquoted performance rights. |
| Class | Unquoted performance rights |
- See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice
| Number acquired | 225,275 unquoted performance rights |
|---|---|
| Number disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
N/A (see “Nature of change” below) |
| No. of securities held after change | 1. 15,331,066 fully paid ordinary shares. 2. 510,660 unquoted options: a. 210,000 unquoted options exercisable at A$0.552 and expire on 20 April 2027; b. 220,500 unquoted options exercisable at A$0.552 and expire on 30 June 2027; and c. 80,160 unquoted options exercisable at A$0.552 and expire on 26 September 2031. 3. 533,020 unquoted performance rights. |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |
Issue of unquoted performance rights under, and subject to, the Acusensus Equity Incentive Plan Rules as part of the remuneration of the Managing Director for the 2026 financial year following shareholder approval at the Acusensus 2025 Annual General Meeting, held on 19 November 2025. |
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) |
N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
N/A |
- See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 2
Appendix 3Y Change of Director’s Interest Notice
| Interest acquired | N/A |
|---|---|
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest after change | N/A |
Part 3 –[+] Closed period
Were the interests in the securities or contracts No detailed above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow N/A the trade to proceed during this period? If prior written clearance was provided, on what N/A date was this provided?
- See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3